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In Brief
Through analysis of de novo mutations in
autism spectrum disorder (ASD), Sanders
et al. find that small deletions, but not
large deletions/duplications, contain one
critical gene. Combining CNV and
sequencing data, they identify 6 loci and
65 genes associated with ASD.
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Analysis of de novo CNVs (dnCNVs) from the full
Simons Simplex Collection (SSC) (N = 2,591 families)
replicates prior findings of strong association with
autism spectrum disorders (ASDs) and confirms six
risk loci (1q21.1, 3q29, 7q11.23, 16p11.2, 15q11.2-
13, and 22q11.2). The addition of published CNV
data from the Autism Genome Project (AGP) and
exome sequencing data from the SSC and the
Autism Sequencing Consortium (ASC) shows that
genes within small de novo deletions, but not within
large dnCNVs, significantly overlap the high-effect
risk genes identified by sequencing. Alternatively,
large dnCNVs are found likely to contain multiple
modest-effect risk genes. Overall, we find strongNeuevidence that de novo mutations are associated
with ASD apart from the risk for intellectual disability.
Extending the transmission and de novo association
test (TADA) to include small de novo deletions re-
veals 71 ASD risk loci, including 6 CNV regions (noted
above) and 65 risk genes (FDR% 0.1).
INTRODUCTION
Autism Spectrum Disorder (ASD) is characterized by impair-
ments in social communication and restricted or repetitive
behavior or interests. Until recently, the genetic etiology of
ASD has remained obscure. Over the last decade, however, a
key role for de novo germline mutation has been established
definitively. Such mutations have led to the discovery of dozens
of ASD risk loci and genes (De Rubeis et al., 2014; Dong et al.,ron 87, 1215–1233, September 23, 2015 ª2015 Elsevier Inc. 1215
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http://dx.doi.org/10.1016/j.neuron.2015.09.0162014; Iossifov et al., 2012, 2014; Neale et al., 2012; O’Roak et al.,
2012; Sanders et al., 2012), as well as yielding important insights
into the genomic architecture and biological mechanisms under-
lying social disability (Chang et al., 2015; Parikshak et al., 2013;
Pinto et al., 2014; Willsey et al., 2013). The Simons Simplex
Collection (SSC), a cohort of simplex ASD families designed to
facilitate the discovery de novo variation (Fischbach and Lord,
2010), has played a central role in this progress. Analysis of the
SSC has demonstrated an excess of rare de novo mutations in
probands versus unaffected siblings across a wide range of mu-
tation types, from copy number variants (CNVs) (Levy et al.,
2011; Sanders et al., 2011), to small insertion/deletions (indels)
(Dong et al., 2014), and single nucleotide variants (SNVs) (Iossi-
fov et al., 2012, 2014; O’Roak et al., 2012; Sanders et al., 2012).
Moreover, the cohort has helped lay a foundation for the creation
of rigorous statistical frameworks to evaluate the association of
de novo mutations (He et al., 2013; Liu et al., 2014; Sanders
et al., 2011, 2012). In combination with exome analyses of addi-
tional large ASD cohorts (De Rubeis et al., 2014; Liu et al., 2013;
Neale et al., 2012), these frameworks have dramatically acceler-
ated gene discovery in ASD.
Previous reports of approximately 1,000 SSC families (Levy
et al., 2011; Sanders et al., 2011) replicated the association be-
tween ASD and de novo CNVs (dnCNVs) (Itsara et al., 2010;
Marshall et al., 2008; Sebat et al., 2007) and the role of CNVs
at 16p11.2 in ASD (Kumar et al., 2008; Marshall et al., 2008;
Weiss et al., 2008). By developing methods to assess the
genome-wide significance of recurrent de novo events, we
identified novel risk loci, including duplications at 7q11.23
(Sanders et al., 2011). The current study extends these ana-
lyses to the entire SSC cohort (N = 10,220 individuals in
2,591 families). We replicate our prior findings in the newly
analyzed SSC cohort; refine the estimates of locus heterogene-
ity for dnCNVs in ASD to between 93 and 246 distinct loci;
confirm the genome-wide significance of four CNV loci
(Table 1); and revisit earlier findings of an increased mutation
burden in females (Figure 2) and genotype-phenotype correla-
tions (Figure 3). In addition, we combine dnCNV findings from
the Autism Genome Project (AGP) (Pinto et al., 2014) with the
SSC data in an omnibus analysis of large-scale dnCNVs that1216 Neuron 87, 1215–1233, September 23, 2015 ª2015 Elsevier Incyields four additional ASD risk loci with a false discovery rate
(FDR) % 0.1 (Table 2).
Recent collaborative efforts have applied exome sequencing
technology to the entire SSC cohort (Iossifov et al., 2014) iden-
tifying 27 ASD associated genes (FDR of % 0.1). In parallel,
33 ASD risk genes (FDR % 0.1) were identified in the Autism
Sequencing Consortium (ASC) cohort (De Rubeis et al., 2014)
with 12 genes identified in both analyses (Table S6), in part
due to the inclusion of 825 SSC trios in the ASC. Importantly,
these approaches to gene discovery that are agnostic to
hypothesized biological mechanism have enabled a series of
similarly agnostic systems biological analyses of ASD. These
have reliably pointed to the contribution of chromatin modifi-
cation and synaptic functioning and provided insights into
the neuroanatomical and developmental dimensions of ASD
pathology, highlighting in particular the contribution of mid-fetal
cortical projection neurons and striatal medium spiny neurons
(Chang et al., 2015; Cotney et al., 2015; Parikshak et al.,
2013; Pinto et al., 2014; Sugathan et al., 2014; Willsey et al.,
2013; Xu et al., 2014).
Completion of genotyping and exome sequencing of the SSC
now allows for a combined analysis of CNV, indel, and SNV data
to assess further the contribution of rare and de novo variation
in these simplex families (Figure 2). We find that small de novo
deletions often contain a single ASD gene of high effect that
overlaps with de novo loss of function (dnLoF; nonsense, canon-
ical splice site, and frameshift indels; also called ‘‘likely gene dis-
rupting’’ [LGD]) mutations (Figure 5). In contrast, large dnCNVs
do not show similar evidence and are likely to contain multiple
genes of low effect. Moreover, expanding the TADA methodol-
ogy (He et al., 2013), we combine evidence from de novo small
deletions, indels, and SNVs to provide a unified statistical quan-
tification of ASD association that, in combination with published
data from the ASC and AGP, identifies 65 ASD risk genes
(FDR % 0.1) (Table 4). These 65 genes form a network of pro-
tein-protein interactions composed of two sub-networks that
are enriched for genes that encode either chromatin regulators
or synaptic proteins (Figure 7). Of note, mutations in male and
female probands are randomly distributed in these networks
rather than clustering on sex-specific genes..
Table 1. Regions with Multiple dnCNVs in the SSC (FDR% 0.1)
Band Location (hg19)
dnCNVs
(del/dup)
RefSeq
Genes Genesa
p Value
(Corrected)
q Value
(FDR)
1q21.1 chr1:146,467,203-147,858,208 5 (0/5) 13 – 0.00008 0.00002
3q29 chr3:195,747,398-197,346,971 3 (3/0) 21 – 0.14 0.05
7q11.23 chr7:72,773,570-74,144,177 4 (0/4) 22 – 0.004 0.001
7q11.23 chr7:73,978,801-74,144,177b 5 (0/5) 2 GTF2I,
GTF2IRD1
0.00008 0.00002
7q11.23 chr7:74,455,447-74,488,775 3 (1/2) 1 WBSCR16 0.31 0.06
15q11.2-13.1 chr15:23,683,783-28,471,141 5 (0/5) 13 – 0.00008 0.00002
15q12 chr15:26,971,834-27,548,820c 6 (0/6) 3 GABRB3,
GABRA5,
GABRG3
1 3 106 6 3 107
15q13.2-13.3 chr15:31,245,880-32,515,849 4 (2/2) 7 – 0.01 0.002
16p11.2 chr16:29,655,864-30,195,048 13 (8/5) 27 – <1 3 1010 <1 3 1010
16q23.3 chr16:82,660,399-83,830,215d 3 (3/0) 1 CDH13 0.13 0.05
22q11.21 chr22:18,886,915-21,052,014 4 (2/2) 36 – 0.31 0.06
aWhere%3 genes are present, they are listed to clarify the genomic location.
bThis is the region of intersection between an atypical dnCNV and the Williams-Beuren Syndrome locus (see Figure S5).
cThis is the region of intersection between an atypical dnCNV and the 15q11.2-13.1 locus (see Figure 6F).
dThree de novo deletions overlap at least one exon of this gene.RESULTS
SNP Genotyping, Sample Selection, and CNV Detection
High-quality SNP genotyping data were generated for 10,220
individuals in 2,591 families from the SSC using the Illumina
Omni2.5, 1Mv3, or 1Mv1 arrays (Figure 1 and Table S1). Of
these, 2,100 families were quartets, consisting of an affected
proband, two unaffected parents, and at least one unaffected
sibling, whereas 491 families were trios with no unaffected
siblings. As described previously, CNVs were predicted using
PennCNV (Wang et al., 2007), QuantiSNP (Colella et al., 2007),
and GNOSIS and merged with CNVision (Sanders et al., 2011).
To improve the specificity of dnCNV predictions, we developed
a novel metric to estimate a per CNV p value (pCNV) based
on the per SNP variability in Log R Ratio (LRR) and the number
of SNPs consistent with a deletion/duplication based on B Allele
Frequency (BAF).
This metric outperformed our prior approach of selecting the
intersection of PennCNV and QuantiSNP calls (Sanders et al.,
2011). Performance was assessed by rediscovery of validated
dnCNVs detected on the 1Mv3 array in biological replicates
run on the higher-resolution Omni2.5 array. A receiver operating
characteristic (ROC) curve was used to compare the two
approaches with an area under the curve (AUC) of 0.82 for
the prior approach compared to 0.99 for the new pCNV metric
(Figure S2). For dnCNVs detectable by microarray, a pCNV
threshold of p % 1 3 109 resulted in 80% sensitivity, similar
to that obtained in our prior analysis, and increased specificity
from 60% to 100%. We therefore elected to use this threshold,
eliminating the need for blinded visual inspection prior to
confirmation (Figure S3). Rare variation was defined as a popu-
lation frequency % 0.1% in either the Database of Genomic
Variation (DGV) (MacDonald et al., 2014) or among all 5,382
SSC parents. This same population frequency threshold wasNeuused in the exome analyses (De Rubeis et al., 2014; Iossifov
et al., 2014).
Overall, we detected 180 autosomal dnCNVs, of which 175
were validated by qPCR (97% confirmation rate); all validations
were performed blinded to affected status. Nine dnCNVs
(5.0%) at six loci were excluded due to germline mosaicism,
based on a mosaic CNV in the parent or the same dnCNV in
multiple siblings (Table S2). The ensuing analysis was performed
on the remaining 166 validated dnCNVs, of which 110 were pre-
sent in the probands of 2,100 quartet families, 34 were present in
the siblings of the same 2,100 families, and 22 were found
among 491 trios (Table S2).
De Novo CNVs Are Reproducibly Associated with
ASD Risk
We first assessed whether our new CNV data replicated prior
findings (Sanders et al., 2011). As observed previously (Levy
et al., 2011; Sanders et al., 2011; Sebat et al., 2007), dnCNVs
are more frequent in cases than controls (Figure 2). In the newly
analyzed data (n = 1,226 quartets), we observed 64 dnCNVs
in probands versus 25 dnCNVs in siblings (0.052 versus
0.020 dnCNVs per individual; ratio: 2.5, 95% CI: 1.6–4.1,
p = 9.3 3 106, one-sided sign test). This increased burden
is observed for both de novo deletions and duplications (p =
0.006 and p = 0.0007 respectively; Table S4). These results are
consistent with our prior findings from a cohort of 874 quartet
families (Sanders et al., 2011). The combined cohort of 2,100
quartet families shows 0.052 dnCNVs per proband compared
to 0.016 dnCNVs per sibling (ratio: 3.1, 95% CI: 2.2–4.7,
p = 6.0 3 1011, one-sided sign test; Figure 2A).
As before (Sanders et al., 2011), a larger number of genes
underlie dnCNVs in probands than siblings. In probands, 0.94
genes per individual were within the boundaries of a dnCNV
compared with 0.12 genes per individual in siblings (ratio: 7.7,ron 87, 1215–1233, September 23, 2015 ª2015 Elsevier Inc. 1217
Table 2. Regions with Multiple dnCNVs in the SSC and AGP (FDR% 0.1)
Band Location (hg19)
dnCNVs
(del/dup)
RefSeq
Genes Genesa
p Value
(Corrected) q Value (FDR)
1q21.1 chr1:146,467,203-147,801,691 9 (1/8) 13 – 6 3 109 2 3 109
2p16.3 chr2:50,145,643-51,259,674b 8 (7/1) 1 NRXN1 1 3 107 4 3 108
3q29 chr3:195,747,398-196,191,434 4 (4/0) 7 – 0.07 0.02
7q11.23 chr7:72,773,570-74,144,177 5 (1/4) 22 – 0.005 0.0008
7q11.23 chr7:72,773,570-73,158,061c 6 (1/5) 10 – 0.0002 0.00003
7q11.23 chr7:73,978,801-74,144,177c 6 (1/5) 2 GTF2I, GTF2IRD1 0.0002 0.00003
15q11.2-13.1 chr15:23,683,783-28,446,765 10 (0/10) 13 – <1 3 1010 <1 3 1010
15q12 chr15:26,971,834-27,548,820d 11 (0/11) 3 GABRA5, GABRB3,
GABRG3
<1 3 1010 <1 3 1010
15q13.2-13.3 chr15:30,943,512-32,515,849 5 (3/2) 7 – 0.005 0.0008
16p11.2 chr16:29,655,864-30,195,048 19 (12/7) 27 – <1 3 1010 <1 3 1010
22q11.21 chr22:18,889,490-21,463,730 8 (4/4) 45 – 1 3 107 4 3 108
22q13.33 chr22:51,123,505-51,174,548 4 (4/0) 1 SHANK3 0.07 0.02
aWhere%3 genes are present they are listed to clarify the genomic location.
bEight dnCNVs overlap at least one exon of this gene.
cThese are the regions of intersection between two atypical dnCNVs and the Williams-Beuren Syndrome locus (see Figure S5).
dThis is the region of intersection between an atypical dnCNV and the 15q11.2-13.1 locus (see Figure 6F).95% CI: 4.2–17.1, p = 3.8 3 1012, one-sided paired Wilcoxon
signed-rank test (WSRT); Figure 2B). The difference between
the individual-based and gene-based analyses is due to the
larger size of dnCNVs in probands (median size 875 kbp in pro-
bands versus 147 kbp in siblings) and higher density of genes
in proband dnCNVs (p = 0.04, linear regression; Figure S4).
Therefore, dnCNVs in probands are more frequent, larger, and
more gene-rich than those observed in siblings.
Previously, we noted that more genes map within dnCNVs
in female probands than male probands, consistent with a fe-
male protective effect (Sanders et al., 2011). This observation
was replicated in an independent cohort of neurodevelopmental
disorders (Jacquemont et al., 2014). In the current analysis, 1.9
genes are found within dnCNVs per proband among 275 female
probands versus 0.8 genes within dnCNVs per proband among
1,825 male probands (ratio: 2.3, 95% CI: 1.0–4.6, p = 0.01,
one-sided unpaired WRST; Figure 2F). We previously noted a
trend toward a higher burden of dnCNVs in female probands
(Sanders et al., 2011). With the increased power afforded by
the current expanded dataset this trend is now significant;
dnCNVs are observed at a rate of 0.076 in female probands
compared to 0.049 in male probands (ratio: 1.6, 95% CI: 0.9–
2.3, p = 0.04, one-sided Fisher’s exact test; Figure 2E). Of
note, these findings are predominantly due to de novo deletions
(ratio: 2.0, 95% CI: 1.0–3.5, p = 0.02, Fisher’s exact test; Fig-
ure 2E) rather than de novo duplications (ratio: 1.1, 95% CI:
0.3–1.9, p = 0.51, Fisher’s exact test). No difference in burden
between the sexes was observed in unaffected siblings (Fig-
ure 2E; Table S4).
Rare Inherited CNVs Show Limited Evidence
of ASD Association
We conducted similar analyses evaluating rare inherited auto-
somal CNVs (riCNVs) (Table S3). As before (Sanders et al.,1218 Neuron 87, 1215–1233, September 23, 2015 ª2015 Elsevier Inc2011), no significant excess of riCNVswas observed in probands
with 5,713 riCNVs in 2,100 probands versus 5,687 riCNVs in
2,100 siblings (2.72 versus 2.71 per individual; ratio: 1.00, 95%
CI: 0.97–1.04, p = 0.70, one-sided paired WRST; Figure 2C). A
slight excess of genes was observed within proband riCNVs
compared to sibling riCNVs (1.72 genes per proband versus
1.52 genes per sibling; ratio: 1.13, 95% CI: 1.04–1.24, p =
0.04, one-sided paired WRST; Figure 2D). These results were
unchanged considering deletions or duplications separately
(Table S4). The findings suggest that, overall, the contribution
of riCNVs detectable by microarray must be small in simplex
ASD. However, the observation of transmitted CNVs mapping
to known ASD risk loci in some affected individuals supports
the conclusion that a small subset of riCNVs does confer
ASD risk.
Given the very modest risks imparted by riCNVs, we antici-
pated little difference in riCNV burden between the sexes,
despite strong evidence for a female protective effect for
de novo mutations. Accordingly, we observed no excess of
riCNVs in female probands versus male probands (2.80
riCNVs/female versus 2.71 riCNVs/male; ratio: 1.03, 95% CI:
0.93–1.15, p = 0.21, one-sided paired WRST). Consistent with
prior microarray analyses (Pinto et al., 2014; Sanders et al.,
2011), but in contrast to analyses of small CNVs detected in
exome data (Krumm et al., 2013; Krumm et al., 2015),
we observe no excess of maternally inherited riCNVs in
probands, with 2,813 riCNVs inherited from the father
compared with 2,680 riCNVs inherited from the mother (p =
0.96, binomial distribution, one-sided). This difference may be
the consequence of varying approaches and detection thresh-
olds in CNV prediction. Similarly, we observed no increased
burden of riCNVs in the mothers of SSC families compared to
the fathers (5,350 in mothers versus 5,505 in fathers, p =
0.93, Binomial test, one-sided) using the detection thresholds.
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Figure 1. Overview of the Analysis
This manuscript describes the analysis of CNVs
predicted from SNP genotyping data in 2,591
families from the SSC (green). The analysis steps
are shown in the middle of the flowchart (purple).
Additional datasets from genomic analysis of the
SSC (blue) and other ASD cohorts (light blue) are
integrated to maximize power. The results of the
analysis are shown in the figures (red) and tables
(light red), along with the text of the manuscript.described in a prior study that reported such a finding (Desachy
et al., 2015).
Recurrent De Novo CNVs Identify Six ASD Risk Loci
The clustering of dnCNVs at a given locus in unrelated probands
can be used to assess association when compared to the null
expectation derived from dnCNVs in unaffected siblings
(Sanders et al., 2011). Using this approach, we previously iden-
tified two loci with genome-wide significance in the SSC and
predicted the discovery of two to three additional regions in
the entire SSC. As anticipated, in the current study, a total of
four loci reach genome-wide significance (p < 0.05; FDR %
0.01): two previously identified (7q11.23 duplications and
16p11.2 [BP4-5] deletions and duplications) and two additional
loci (1q21.1 duplications and 15q11.2-13.1 [BP2-3] duplica-Neuron 87, 1215–1233, Septions). Relaxing the detection threshold
to an FDR % 0.1 identifies three further
loci: 3q29 deletions, 22q11.2 deletions
and duplications, and deletions at Cad-
herin 13 (CDH13) (Table 1). No locus
met this threshold in the sibling data.
Integrating the SSC data with previ-
ously publisheddnCNVs identified among
2,096 trios from the AGP (Pinto et al.,
2014) identifies two additional intervals
reaching genome-wide significance: de-
letions at Neurexin 1 (NRXN1) and dele-
tions and duplications at 22q11.2
(Table 2). Moreover, at an FDR threshold
of%0.1, two further loci are identified: de-
letions at 3q29 and deletions at 22q13.33
that include the gene SHANK3. No further
dnCNVs were reported in the AGP at the
CDH13 locus, resulting in an FDR q value
of 0.20 for the combined analysis. All
eight loci (Table 2) have previously been
implicated in ASD (Bucan et al., 2009; Ku-
mar et al., 2008; Leblond et al., 2014;
Marshall et al., 2008; Mefford et al.,
2008; Moreno-De-Luca et al., 2013b;
Sanders et al., 2011; Weiss et al., 2008).
More than 200 De Novo CNV Loci
Carry ASD Risk
By comparing the burden of dnCNVs in
siblings to that of probands, and consid-ering the degree of dnCNV recurrence in probands, we previ-
ously estimated a total of 234 distinct dnCNV loci that mediate
ASD risk. Repeating this calculation (Supplemental Experimental
Procedures) in the entire SSC, we estimate a total of 93 ASD risk
loci for dnCNVs, 61 loci for de novo deletions, and 37 loci for de
novo duplications. In the combined SSC and AGP cohort, we es-
timate 246 total dnCNV risk loci, 181 loci for de novo deletions,
and 168 loci de novo duplications.
The Presence of a De Novo Mutation Is Associated with
a Reduction in IQ
Previously, we reported that the presence of a dnCNV was asso-
ciatedwith a lower IQ in probands but that IQwas aweak predic-
tor of de novo status (Sanders et al., 2011). Recent reports have
described a similar reduction in IQ in the presence of a de novotember 23, 2015 ª2015 Elsevier Inc. 1219
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Figure 2. CNV Burden in the SSC
(A) The rate of dnCNVs per individual in probands and family-matched sibling controls for deletions (red) and duplications (blue) are compared for new families
(n = 1,226; left), previously published families (n = 874; middle), and the combination of these two cohorts (n = 2,100; right).
(B) The analysis presented in (A) is repeated except the number of genes within dnCNVs per individual is displayed rather than the rate of dnCNVs per individual.
(C and D) The analyses presented in (A) and (B) are repeated using riCNVs instead of dnCNVs.
(E) The rate of dnCNVs per individual is shown for probands (left three bars) and siblings (right three bars). Within each group, the rate of dnCNVs is shown for all
individuals (left), females (middle), and males (right). No statistical comparison was made between probands and siblings for this analysis.
(F) The analysis in (E) is repeated except the number of genes within dnCNVs per individual is displayed rather than the rate of dnCNVs per individual.
Statistical significance was calculated using a one-sided sign test for (A), a one-sided paired Wilcoxon ranked-sum test (WRST) for (B)–(D), and a two-sided
unpaired WRST for (E) and (F). Whiskers show the 95% confidence intervals throughout (A)–(F).
1220 Neuron 87, 1215–1233, September 23, 2015 ª2015 Elsevier Inc.
LoF (dnLoF) mutation (Iossifov et al., 2014; Robinson et al., 2014;
Samocha et al., 2014). Using the combinedCNV and exome data
in the SSC, we considered how sex and type of de novomutation
interact with non-verbal IQ (NVIQ).
For bothmales and females, we observe a reduction in NVIQ in
the presence of either a dnLoF or dnCNV (8 point decrease in
males, p = 4 3 106; 18 point decrease in females, p = 0.006;
one-sided WRST; Figure 3A). In males there was no significant
difference in the NVIQ between de novo deletions, duplications,
or dnLoFs. In females, there was no difference in NVIQ between
de novo deletions and duplications (p = 0.61); however, the
median decrease in NVIQ was 12.5 points for dnLoF compared
to 26 points for a dnCNV (p = 0.01; Figure 3A).
Overall, probands with an NVIQ below the proband median
(89) had a 1.7-fold higher rate of de novo mutations compared
to those with an NVIQ above the median (95% CI: 1.4–2.1;
p = 1 3 107; one-sided WRST) and this effect was more pro-
nounced in females (2.2-fold 95% CI: 1.3–3.8; p = 0.001) than
males (1.6-fold 95% CI: 1.3–2.0; p = 3 3 105).
While a reduction in NVIQ is clearly associated with a dnCNV
or dnLoF, we still observe a robust excess of de novo mutations
in both male and female probands with an NVIQ between
91 and 110 compared to de novo mutations in siblings (p =
63 106 for males; p = 33 103 for females; WRST; Figure 3B).
Furthermore, for the mutations with the highest confidence
(FDR% 0.1; Tables 2 and Table 4), we observe an excess burden
in males even at an IQ above 130 (p = 0.04; WRST; Figure 5C).
Therefore, despite the association between NVIQ and de novo
status, a low NVIQ does not guarantee detecting a de novo
mutation and a high NVIQ does not exclude an ASD-associated
de novo mutation.
Phenotypic Features Associated with De Novo
Mutations
Using the rich phenotypic data in the SSC, we tested whether
other factors, along with sex and NVIQ, were associated with
the presence of a dnCNV or dnLoF. The presence of an unaf-
fected sibling increased the likelihood of observing a dnCNV
or dnLoF (p = 0.001; WRST; Figures 3D and 3E) and this effect
was amplified in the presence of multiple unaffected siblings.
Similarly a history of seizures was associated with a higher de
novo rate (p = 0.0008; WRST; Figures 3D and 3E); of note, this
increase was observed equally for febrile and afebrile seizures
(Figure S7). Similarly, a head circumference deviation of over 1
SD in either direction (Chaste et al., 2013) was associated with
increased mutational burden. In contrast, we observed no
difference in de novo burden in the presence of developmental
regression or higher paternal or maternal age (Figure S7).
De Novo Mutations Contribute to ASD Risk in over
10% of Simplex Cases
The family structure of the SSC, and the availability of both SNP
genotyping and exome data (Iossifov et al., 2014), offer an
exceptional opportunity to explore the genomic architecture of
ASD risk factors. By subtracting the rate of de novo mutations
in siblings from the rate in probands, we can estimate the fraction
of observed proband de novo mutations that contribute to ASD
risk. In probands, we estimate that 70% (95% CI: 55%–80%)Neuof dnCNVs and 46% (95% CI: 32%–56%) of dnLoF mutations
carry ASD risk (Table 3). Both estimates are higher in females
than males (Table 3).
By subtracting the percentage of siblings with R1 de novo
mutation from the percentage of probands with R1 de novo
mutation we can estimate the percentage of cases in whom a
de novo mutation is contributing ASD risk. Based on this calcu-
lation, we estimate that 4% (95% CI: 3%–6%) of cases have a
dnCNV mediating ASD risk and 7% (95% CI: 5%–9%) of cases
have a dnLoF mediating ASD risk. In total, 11% (95% CI: 8%–
13%) of simplex cases have a dnCNV and/or dnLoF mediating
ASD risk (Table 3). In females, de novo mutations play a greater
role in the ASD phenotype, contributing to ASD risk in 17% (95%
CI: 11%–23%) of female probands and 10% (95% CI: 7%–12%)
of male probands. Of note, these are conservative estimates for
the overall contribution of de novo mutations to simplex ASD
since they do not include very small CNVs, balanced structural
variation, or variants discovered with sequencing aside from
dnLoF.
ASD Risk Varies Based on the Size of the Mutation
To further understand the genomic architecture of ASD in the
SSC, we estimated the burden of both SNVs and CNVs in pro-
bands compared to their unaffected siblings divided by variant
size and mode of inheritance (Figure 4). Variants were divided
into six bins based on size, the first bin was nonsense/splice
site SNVs and the remaining five bins were CNVs covering: 1
gene, 2–3 genes, 4–10 genes, 11–20 genes, and >20 genes. For
this analysis only, frameshift indels were excluded due to the
absence of accurate population frequency data to identify rare in-
herited variants. Of note, we previously showed that both the
burden and proband:sibling ratio of de novo frameshift indels is
similar to that of de novo nonsense/splice site mutations (Dong
et al., 2014).
De novo mutations were observed more frequently in pro-
bands than siblings across the range of sizes. A similar proband:
sibling ratio is observed for de novo nonsense/splice site and
small de novo deletions, suggesting a similar fraction of these
events mediate ASD risk. A higher ratio is observed for large
dnCNVs. In contrast, no significant excess of rare inherited
CNVs is observed at any size, though there is a trend toward
an excess in probands for larger structural events (Figure 4).
Large De Novo CNVs and De Novo Point Mutations
Target Different Genes
Multiple efforts have been made to fine map large multi-genic
dnCNVs in search of one or a small number of risk genes. Using
dnCNV data from 4,687 probands in the SSC (this manuscript;
Levy et al., 2011; Sanders et al., 2011) and the AGP (Pinto
et al., 2014) alongside exome data from 3,982 probands in the
SSC (Iossifov et al., 2014) and ASC (De Rubeis et al., 2014), we
sought to address the broader question of whether, overall, the
overlap between genes within dnCNVs and those altered by
dnLoF mutations (Figure 5A) was greater than expected by
chance, as would be predicted if large dnCNVs included only a
small number of risk genes.
To address this question, we askedwhether therewas anover-
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Table 3. Contribution of De Novo Mutations to ASD Risk
Category of
de novo mutation
Mutations per sample Percent of mutations contributing to ASD risk (95% CI)
Probands Siblings Probands
All Male Female All All Male Female
Deletions 0.03 0.03 0.06 0.01 69.1% (43.2%–85.4%) 64.6% (38.7%–83.2%) 83.7% (66.2%–91.9%)
Duplications 0.03 0.03 0.03 0.01 70.8% (48.3%–86.8%) 70.8% (55.3%–88.6%) 70.9% (0.0%–88.2%)
All CNVs 0.06 0.05 0.09 0.02 69.9% (55.1%–79.6%) 67.7% (49.2%–79.1%) 79.7% (56.9%–88.5%)
Nonsense 0.06 0.06 0.05 0.03 52.9% (33.8%–68.7%) 53.9% (34.6%–66.4%) 44.5% (0.0%–70.4%)
Splice Site 0.02 0.02 0.06 0.01 52.4% (18.9%–73.7%) 39.6% (0.0%–72.3%) 80.8% (57%–91.6%)
Frameshift 0.08 0.08 0.10 0.05 38.9% (14.8%–51.2%) 37.4% (21.1%–52.9%) 47.8% (4.9%–65.6%)
All LoF 0.17 0.16 0.21 0.09 45.9% (31.8%–55.5%) 43.9% (31.4%–53.8%) 56.6% (41.1%–67.7%)
All LoFs and CNVs 0.22 0.21 0.29 0.11 52.2% (45.2%–59.7%) 50.0% (41.0%–58.9%) 63.4% (49.4%–71.8%)
Category of
de novo mutation
Percent of cohort with a mutation Percent of cases with a mutation contributing to ASD risk (95% CI)
Probands Siblings Probands
All Male Female All All Male Female
Deletions 3.1% 2.7% 6.0% 1.0% 2.2% (1.1%–3.2%) 1.8% (0.8%–2.5%) 5.0% (2.3%–8.4%)
Duplications 2.7% 2.7% 2.8% 0.8% 1.9% (1.2%–2.6%) 1.9% (1.0%–3.0%) 2.0% (0.2%–4.3%)
All CNVs 5.8% 5.3% 8.7% 1.7% 4.1% (2.6-5.7%) 3.6% (2.3%–4.9%) 7.0% (3.2%–11.4%)
Nonsense 5.9% 6.0% 5.0% 2.8% 3.1% (1.4-4.4%) 3.2% (1.8%–4.9%) 2.2% (0.0%–6.2%)
Splice Site 2.4% 1.9% 6.0% 1.1% 1.3% (0.5-2.3%) 0.7% (0.0%–1.5%) 4.8% (1.5%–8.8%)
Frameshift 7.8% 7.7% 8.7% 4.8% 3.0% (1.2-4.8%) 2.9% (1.2%–4.4%) 3.9% (0.2%–7.5%)
All LoF 15.4% 14.9% 18.8% 8.5% 6.9% (4.9-8.9%) 6.4% (3.9%–8.8%) 10.3% (6.3%–16.2%)
All LoFs and CNVs 20.6% 19.7% 26.6% 10.1% 10.5% (7.8-13.1%) 9.6% (6.8%–12.0%) 16.6% (11.4%–22.6%)and de novo silent (dnSilent) mutations in the 1,794 unique
genes within 119 large dnCNVs in probands. As there are very
few large dnCNVs in siblings, we elected to use the number
of proband dnLoF, dnMissense, and dnSilent mutations in the
16,564 genes not within any proband dnCNVs to calculate
the null distribution. We observed no evidence of an excess
of mutations from exome data in the genes within large
dnCNVs, with 0.024 dnLoFs per gene within large dnCNVs
compared with 0.031 dnLoFs per gene outside of dnCNVs
(OR: 0.8; 95% CI: 0.5–1.0; p = 0.10, two-sided Fisher’s
exact test; estimates corrected for gene mutability based
on size and GC content; Figure 5C). Similarly, no difference
was observed when we restricted the analysis of point
mutations to dnMissense or dnSilent separately, when we
considered various types of dnCNVs including large deletions,Figure 3. Genotype-Phenotype Correlations in the SSC
(A) The violin plot shows the distribution of non-verbal IQ (NVIQ) in male proband
four sets: probands with no dnCNVs or dnLoFmutations (gray), probands with a d
with a dnLoF (purple). Individuals with multiple de novo events in more than one
boxplot shows the median and interquartile range (IQR). The horizontal black lines
dashed line extends this estimate for females to the y axis. Statistical significan
plications together and deletions, duplications, and LoF together are not shown.
(B) The percent of probands with a dnLoF or dnCNV (y axis) is shown for male (g
difference in de novo rate compared with siblings (horizontal dashed line at 10.7%
intervals. The size of the circles represents the number of individuals in each gro
(C) The analysis in (B) is repeated considering only de novo mutations at loci wit
(D) The percent of probands with a dnLoF or dnCNV (y axis) is shown for three phen
probands using a one-sided Fisher’s exact test; the whiskers show the 95% confi
each group ranging from 170 to 2,177. The head size Z score is for the genetic d
(E) The analysis in (D) is repeated considering only de novo mutations at loci wit
Neularge duplications, and large dnCNVs with the strongest evi-
dence of association with ASD based on recurrence (FDR %
0.1), or when we considered the SSC cohort independently
(Figures 5C and S8).
Small De Novo Deletions and De Novo LoFs Target a
Common Set of Genes
In contrast to large dnCNVs, a similar analysis considering only
small dnCNVs (N % 7 genes) (Figure 5C) showed an excess of
dnLoF and dnMissense mutations. The 130 unique genes
within 73 small de novo deletions in probands contained
0.127 dnLoF per gene compared with 0.031 dnLoFs per
gene outside of dnCNVs (OR: 4.4; 95% CI: 2.4–17.5; p = 3.8 3
106, two-sided Fisher’s exact test; estimates corrected for
gene mutability; Figure 5C). A modest excess of dnMissenses (left four violins) and female probands (right four violins). Each sex is split into
e novo deletion (red), probands with a de novo duplication (blue), and probands
category were included in all of the corresponding distributions. The overlaid
show the median for the probands with no dnCNVs or dnLoFs in each sex; the
ce was calculated using a one-sided WRST; violin plots of deletions and du-
reen) and female (pink) probands binned by NVIQ (x axis). p values reflect the
) using a one-sided Fisher’s exact test; the whiskers show the 95% confidence
up ranging from 4 to 694.
h an FDR% 0.1.
otypic factors. p values reflect the difference in de novo rate between groups of
dence intervals. The size of the circles represents the number of individuals in
eviation (Chaste et al., 2013).
h an FDR% 0.1.
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Figure 4. Association of Genetic Factors
with ASD across the Size Spectrum
(A) The number of rare autosomal de novo muta-
tions per individual are shown for dnLoF (nonsense
and splice site only) in 1,911 SSC probands (pur-
ple) and 1,911 family-matched sibling controls
(green) and for dnCNVs binned into five sizes by
gene content in 2,100 SSC probands (purple) and
2,100 family-matched sibling controls (green). A
significantly higher burden of de novo mutation is
observed across the size range with the exception
of ‘‘1 gene’’; one-sided sign test; whiskers repre-
sent 95% confidence intervals.
(B) The proband:sibling ratio for each size of de
novo mutation is shown by the black diamonds
and the black dashed line; whiskers represent
the 95% confidence interval estimated by boot-
strapping. The ratio is also shown for deletions
(red) and duplications (blue).
(C) The analysis shown in (A) is repeated for rare
inherited variants in the same individuals. Signifi-
cance was estimated using a one-sided paired
Wilcoxon ranked-sum test with only rare inherited
nonsense/splice site variants reaching nominal
significance.
(D) The analysis in (C) is repeated for rare inherited
variants in the same individuals.mutations (OR: 1.9; 95% CI: 1.2–2.9; p = 0.003), but not dnSilent
mutations, was also observed (Figure 5C).
To demonstrate that this result was driven by ASD association,
we repeated the analysis substituting in the sibling data. These
were not used for the primary analysis due to the sparseness
of de novo events in the siblings and the consequent reduction
in power. There was no evidence of enrichment of sibling dnLoFs
within proband small de novo deletions (p = 0.71, two-sided
Fisher’s exact test), proband dnLoFs within sibling small
de novo deletions (p = 0.24, two-sided Fisher’s exact test),1224 Neuron 87, 1215–1233, September 23, 2015 ª2015 Elsevier Inc.or sibling dnLoFs within sibling small
de novo deletions (p = 1.00, two-sided
Fisher’s exact test).
To ensure that the overlap between
exomemutations and small de novo dele-
tions was not driven by a single dataset,
we next divided the exome data by cohort
(SSC versus ASC) and also considered de
novo mutations identified by exome
sequencing in the Deciphering Develop-
mental Disorders study (Deciphering
Developmental Disorders Study, 2015),
an independent cohort of individuals
with developmental disability. Similarly,
we split the dnCNVs by cohort (SSC,
AGP, and the combination of SSC and
AGP). Enrichment of de novo point
mutations was consistently observed
within small de novo deletions, but not
for the other three categories of dnCNV
(Figure 5D). Of note, these analyses arerobust to variation of the number of genes used to define small
versus large dnCNVs between three and ten (Figure S9).
We also compared the genes within small de novo deletions
to five datasets previously reported to intersect with ASD-asso-
ciated genes. All five datasets showed enrichment in genes in
small de novo deletions in probands, specifically: two datasets
of genes that show evolutionary constraint (p = 0.04, p = 1 3
105, logistic regression) (Petrovski et al., 2013; Samocha
et al., 2014), one dataset of genes that are targeted by the
Fragile X protein FMRP in mouse brain (p = 4 3 108, logistic
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Figure 5. Small De Novo Deletions Are
Enriched for Exome Mutations
(A) 2,080 unique genes are identified within pro-
band dnCNVs (red) and 522 unique genes have
dnLoFs in probands (purple); 58 unique genes are
observed in both these datasets.
(B) The median number of genes within validated
dnCNVs in the SSC is seven; this threshold is used
to distinguish small and large dnCNVs.
(C) The number of de novo mutations per gene
observed with exome sequencing of the SSC and
ASC are shown in different groups of genes based
on dnCNV overlap. Mutation rates are normalized
for gene mutability based on gene size and GC
content. Exome mutations are divided into silent
(gray), missense (green), and LoF (purple). No
excess of exome mutations is observed in the
2,080 genes within dnCNV regions compared
to the 16,564 genes outside of dnCNVs. Dividing
the dnCNV regions by size (%7 genes versus
>7 genes) and type (deletion versus duplication)
reveals strong enrichment for dnLoF (p = 43 106,
Fisher Exact Test) and dnMissense (p = 0.003) in
small de novo deletions only.
(D) The enrichment of genes within dnCNVs is
shown by the size and shade of the circle (red and
large = high degree of enrichment; blue and small =
modest degree of enrichment); only results
reaching nominal significance (hypergeometric
test) are shown. Small de novo deletions show
consistent enrichment for dnLoF and dnMissense
mutations across three cohorts: SSC, Autism
Sequencing Consortium (ASC), and Deciphering
Developmental Disorders (DDD). This result is
observed for dnCNVs detected in the SSC and
Autism Genome Project (AGP) independently and
in combination.regression) (Darnell et al., 2011), and two datasets of genes that
are bound by CHD8 using ChIP-seq (p = 0.04, p = 0.03, logistic
regression) (Cotney et al., 2015; Sugathan et al., 2014). In
contrast, none of these datasets were enriched in genes in
small de novo deletions from the SSC siblings (p = 0.99,
p = 0.46, p = 0.99, p = 0.99, p = 0.97, respectively; logistic
regression).
The consistently strong enrichment of dnLoF mutations in
small de novo deletions raises the possibility that these two clas-
ses of mutation target a common set of genes that mediate ASD
risk. Based on this hypothesis, we would expect this enrichment
to be the most dramatic for the genes with the strongest evi-
dence of ASD association in the exome data. To test this hypoth-
esis, we used the transmitted and de novo association (TADA)Neuron 87, 1215–1233, Septest to combine exome data from the
SSC and ASC (Table S5). The model
was built on the background of the pub-
lished TADA analysis from the ASC,
including the ASC rare inherited exome
variants (De Rubeis et al., 2014). We elec-
ted not to include the rare inherited
exome variants from the SSC, since these
were not analyzed in a consistent mannerto the ASC, their confirmation rate was not known, and their
contribution to the TADA score is minimal. The TADA test gener-
ates an FDR q value for every gene based on the evidence from
exome sequencing and the per gene mutability (He et al., 2013).
A low q value represents strong evidence for ASD association,
therefore if dnLoF and de novo small deletions target a common
set of genes we would expect specific genes within the deletions
to have lower than expected TADA scores.
To assess the distribution of TADA q values in small de novo
deletions, it was necessary to determine the expected q values
under the null hypothesis (i.e., that small de novo deletions
and exome variants do not target a common set of genes).
A permutation test was used based on the mutability of genes
within a dnCNV and the ability to detect these dnCNVs on atember 23, 2015 ª2015 Elsevier Inc. 1225
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Figure 6. Small De Novo Deletions Intersect
with ASD Genes
(A) The TADA FDR q value is an assessment of
ASD association based on de novo and inherited
variants identified by exome sequencing in the
context of estimates of gene mutability. A low
TADA FDR q value (high –log(q)) represents
stronger ASD association. Observed TADA –log(q)
values are shown against expected TADA –log(q)
values derived from permutation testing. Each
point represents one gene within a proband
dnCNV. The black line represents random sam-
pling of the genome, with no increased overlap
between genes in dnCNVs and the genes identified
by exome sequencing in ASD. Small de novo de-
letions (red, on the left) deviate dramatically from
this expectation while the other three categories
show expected or slightly less than expected
enrichment for ASD genes. The four genes with
the strongest evidence for ASD association are
labeled for the small de novo deletions (left). The
individual genes with the highest -log(q) value
(Table S6) within each of six large dnCNV loci with
the strongest evidence for ASD association
(Table 2) are indicated by the locus name (right).
(B) Three small de novo deletions and one dnLoF
are observed in SHANK2.
(C) Two small de novo deletions and five dnLoF
are observed in ARID1B.
(D) One small de novo deletion and one dnLoF are
observed in KATB2.
(E) One small de novo deletion and one dnLoF are
observed in TRIP12.
(F) Of the six large dnCNV loci with the strongest
evidence forASDassociation (Table2) the15q11.2-
13 contains the gene with the lowest -log(q) value
from the exome data: GABRB3.microarray (a factor of gene size including introns, number
of SNPs, and the interaction of these two terms; Figures
S10–S12). Comparing the expected TADA q values from per-
mutated genes (median q value of 100 permutations) with the
observed TADA q values showed that over half the genes
within small de novo deletions showed evidence of overlap
with the exome data (Figure 6A). In contrast, like the large
dnCNVs, the q values of de novo small duplications match
expectation closely (Figure 6A). Therefore, after correcting for
the number of genes within a CNV, small de novo deletions
are enriched for ASD risk genes identified by exome data,
while small de novo duplications (Figure 6A) and large dnCNVs
(Figure 6B) are not.1226 Neuron 87, 1215–1233, September 23, 2015 ª2015 Elsevier Inc.The observed distribution of TADA
q values would be consistent with a
model in which a single gene within
each de novo small deletion is respon-
sible for all of the ASD risk from the
dnCNV. In keeping with this model there
are no examples of a small de novo dele-
tion in which a dnLoF is observed in
more than one gene, There are, in
contrast, several examples of multiplesmall de novo deletions in unrelated individuals targeting the
same gene (e.g., NRXN1) or multiple dnLoFs targeting the
same gene (e.g., SYNGAP1, ARID1B; Figure 6C).
Integrating Small De Novo Deletions with Exome Data
Reveals 65 ASD Risk Genes
Because small de novo deletions and exome mutations appear
to target a common set of ASD risk genes, we integrated the
evidence from the small de novo deletions into the TADA model
to enhance gene discovery (Supplemental Experimental Proce-
dures). Applying this model to the entire SSC cohort identified
eight ASD genes (Table S6) in addition to the 27 identified previ-
ously at an FDR of % 0.1 (Iossifov et al., 2014). Integrating the
Table 4. Integrating Small De Novo Deletions in TADA Identified 65 ASD Genes
dnLoF Count FDR% 0.01 0.01 < FDR% 0.05 0.05 < FDR% 0.1
R2 ADNP, ANK2, ARID1B, ASH1L, CHD2,
CHD8, CUL3, DSCAM, DYRK1A, GRIN2B,
KATNAL2, KDM5B, KMT2C, NCKAP1,
POGZ, SCN2A, SUV420H1, SYNGAP1,
TBR1, TCF7L2, TNRC6B, WAC
BCL11A, FOXP1, GIGYF1,
ILF2, KDM6B, PHF2, RANBP17,
SPAST, WDFY3
DIP2A, KMT2E
1 NRXN1, PTEN, SETD5, SHANK2,
SHANK3, TRIP12
DNMT3A, GABRB3, KAT2B,
MFRP, MYT1L, P2RX5
AKAP9, APH1A, CTTNBP2, ERBB2IP,
ETFB, INTS6, IRF2BPL, MBD5, NAA15,
NINL, OR52M1, PTK7, TRIO, USP45
0 – MIB1, SLC6A1, ZNF559 ACHE, CAPN12, NLGN3
Genes with a small de novo deletion are in bold. FDR, false discovery rate.data from the recent ASC exome analysis (De Rubeis et al., 2014)
and small de novo deletions from the AGP (Pinto et al., 2014) and
a separate analysis of the SSC (Levy et al., 2011) identified 65
ASD genes (FDR % 0.1; Table 4; Table S6). Of these, 27 had
not previously met this threshold in the independent datasets
(21 added by the combined TADA analysis, 6 by the inclusion
of small de novo deletions).
At the more conservative threshold of FDR% 0.01, we identify
28 ASD genes. Of these, 12 genes (ASH1L, KMT2C, NCKAP1,
NRXN1, PTEN, SETD5, SHANK2, SHANK3, TCF7L2, TNRC6B,
TRIP12, andWAC) had not previously met this threshold in inde-
pendent genome-wide datasets (4 added by the combined
TADA analysis, 8 by the inclusion of dnCNVs).
Several of the 65 ASD risk genes were previously described in
the literature but had not met detection thresholds in the exome
data. These include NRXN1, SHANK2 (Figure 6B), and SHANK3.
While these genes have been previously considered definitive
ASD risk loci (Berkel et al., 2010; Durand et al., 2007; Leblond
et al., 2014; Pinto et al., 2010; Sanders et al., 2011), the current
analysis allows a side-by-side comparison of the evidence in
favor of association of these loci with the other genes identified
in recent studies.
Many of the novel ASD risk genes were identified through the
integration of the SSC and ASC datasets using the TADA meth-
odology. This set of genes includes the ATPase gene Spastin
(SPAST) that is associated with autosomal-dominant spastic
paraplegia (Hazan et al., 1999) but was predicted to be associ-
ated with ASD by virtue of its relationship to other ASD genes
in gene co-expression using the DAWN framework (Liu et al.,
2014). The gene DNA-methyltransferase 3 alpha (DNMT3A), a
key gene in the establishment of genomic imprinting in the em-
bryo (Kaneda et al., 2004), is also identified by combining the
SSC and ASC data. De novo heterozygous missense mutations
in this gene have recently been associated with an overgrowth
syndrome characterized by tall stature, distinctive facial appear-
ance, and intellectual disability (Tatton-Brown et al., 2014). Three
individuals in the SSC had a non-synonymous de novo mutation
in DNTM3A: a boy with a NVIQ of 71 had a de novo frameshift
mutation; a boy with an NVIQ of 82 had a de novo missense mu-
tation (V665L); and a girl with an NVIQ of 49 also had a de novo
missense mutation (P904L). Consistent with an overgrowth syn-
drome, all three individuals had heights and weights above the
95th percentile despite normal body mass index (BMI).NeuFinally, several novel genes are added to the list through the
combination of small de novo deletions and dnLoFs. These
include the p300/CBP-associated transcriptional regulator
K(lysine) acetyltransferase 2B (KAT2B; Figure 6D) that has not
previously been associated with neurodevelopmental abnormal-
ities, the E3 ubiquitin ligase Thyroid hormone receptor interactor
12 (TRIP12; Figure 6E) in which a further dnLoF has been identi-
fied through targeted sequencing (O’Roak et al., 2014), and
Methyl-CpG binding domain protein 5 (MBD5) that has previ-
ously been identified as the critical gene at the 2q23.1 locus
through the observation of small de novo deletions and is asso-
ciated with microcephaly, intellectual disability, neurodevelop-
mental abnormalities, and autistic features (Hodge et al., 2014;
Talkowski et al., 2012).
ASD-Associated Genes Form a Protein-Protein
Interaction Networkwith TwoSubnetworks Enriched for
Chromatin Regulating and Synaptic Genes
The integration of the small de novo deletions and exome data
using the TADA metric resulted in a considerably expanded set
of high confidence ASD genes. We therefore considered how
this list of genes could inform our view of the etiology of ASD.
Gene ontology analysis of the 65 genes with an FDR% 0.1 using
DAVID (Dennis et al., 2003) showed strong enrichment for chro-
matin regulation (3.2-fold over expectation; Benjamini Hochberg
corrected (BHC) p = 0.0004), with eight genes contributing to this
process (ARID1B, ASH1l, CHD8, DNMT3A, KMT2C, KMT2E,
KDM5B, and SUV420H1); no other distinct processes showed
significant enrichment.
We next considered whether there was evidence of protein-
protein interaction (PPI) using DAPPLE (Rossin et al., 2011).
A single network was derived from the 28 genes with an
FDR% 0.01 (p = 0.05 for direct interactions; p = 0.02 for indirect
interactions). The resulting network shows a clear distinction into
two subnetworks (Figure 7A); using DAVID, one subnetwork is
enriched for synaptic/neuronal genes (9.5-fold enrichment;
BHC p = 1 3 1014), while the other subnetwork is enriched for
chromatin regulator/transcription genes (6.6-fold enrichment;
BHC p = 8 3 108). Of note, the gene Branched Chain Ketoacid
Dehydrogenase Kinase (BCKDK) is drawn into the chromatin
subnetwork by virtue of its interactions with both CHD8 and
CHD2. This gene was previously associated with ASD through
the observation of homozygous variants that disrupt BCKDKron 87, 1215–1233, September 23, 2015 ª2015 Elsevier Inc. 1227
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function in three consanguineous families (Novarino et al., 2012)
resulting in markedly reduced plasma levels of branched chain
amino acids. This result may indicate a functional relationship
between ASD-associated chromatin regulators and a metabolic
cause of ASD.
Repeating the DAPPLE analysis with all 65 genes (FDR% 0.1)
resulted in one large network (p = 0.02 for indirect interactions).
The distinct divide between synaptic/neuronal and chromatin
regulator/transcription subnetworks also persists (10.5-fold
enrichment, BHC p = 6 3 1018 and 14.5-fold enrichment,
BHC p = 1 3 1014, respectively; Figure 7B).
Mutations in Male and Female Cases Target a Common
Set of Genes
One possible explanation for the increased male prevalence in
ASD would be a set of genes in which mutations contribute
ASD risk in males only. Our data do not support this hypothesis.
In the 65 ASD genes (FDR% 0.1), there were 109 dnLoF muta-
tions or small de novo deletions in male probands compared
to 33 in female probands. If the mutations targeted a common
set of genes, irrespective of sex, we would expect 19 genes to
include mutations from both sexes. The presence of male-spe-
cific risk genes would result in fewer than 19 genes. In contrast,
we observed 20 genes with amutation from both sexes (p = 0.97;
permutation analysis). This result was not altered by restricting
to genes in the chromatin PPI subnetwork (9 expected, 10
observed; p = 0.73) or in the synaptic PPI subnetwork (6 ex-
pected, 7 observed; p = 0.76; Figure 7B).
DISCUSSION
Analysis of CNVs detected in 2,591 families from the SSC high-
lights the key role of de novo mutations in the etiology of ASD.
We replicate prior findings that dnCNVs are associated with
ASD through the observation of an increased burden in pro-
bands compared to unaffected sibling controls. Using the sibling
distribution of dnCNVs to establish rigorous statistical thresh-
olds, we previously identified two loci at genome-wide signifi-
cance (deletions and duplications at 16p11.2 and duplications
at 7q11.23) and, as predicted (Sanders et al., 2011), identified
two further loci: 1q21.1 duplications and 15q11.2-13.1 duplica-
tions (Table 1). Including additional dnCNV data (Levy et al.,
2011; Pinto et al., 2014) identifies an additional two loci: deletions
at NRXN1 and deletions and duplications at 22q11.2. Relaxing
the threshold to an FDR % 0.1 identifies two more: 3q29 dele-
tions and SHANK3 deletions, leading to a total of eight ASD
risk loci from dnCNVs (Table 2); however, two of these loci
involve only a single gene (NRXN1 and SHANK3) and conse-
quently were included in the list of ASD risk genes, leading to a
total of 6 loci and 65 genes.Figure 7. Protein-Protein Interaction Networks in ASD
(A) 28 ASD genes identified with a TADA FDR% 0.01 were submitted as seeds to
circles in red and/or blue based on the sex of the ASD cases in whom the mutatio
does not differ from expectation (p = 0.97). Protein-protein interactions are shown
indirect connections. The network has a clear distinction into two halves (shown
DAVID (Dennis et al., 2003) and the top gene ontology terms are shown with Ben
(B) The analysis in (A) was repeated using all 65 ASD genes with an FDR% 0.1 (
NeuThe majority of these CNV loci are also associated with devel-
opmental delay (Coe et al., 2014) and, to a lesser extent, schizo-
phrenia. The overlap with schizophrenia loci appears to be more
selective; for example, 16p11.2 duplications are associated with
schizophrenia, while 16p11.2 deletions are not (Szatkiewicz
et al., 2014). These observations are consistent with a model in
which CNVs contribute risk to a number of neuropsychiatric dis-
orders (Moreno-De-Luca et al., 2013a; Stefansson et al., 2014);
however, the extent of this risk varies between phenotypes for
each locus (Moreno-De-Luca et al., 2014).
Our prior exome analysis demonstrated that the observation of
even a small number of dnLoF mutations in the same gene
among unrelated individuals could provide considerable statisti-
cal power to establish association (Sanders et al., 2012). The
TADA test has extended this approach further and provides a
framework to incorporate case-control data, transmitted vari-
ants, and missense mutations alongside dnLoF, resulting in a
single metric of genome-wide association (He et al., 2013).
Applying this model to 3,871 ASD cases and 9,937 controls in
the ASC yielded 33 ASD risk genes (FDR % 0.1) (De Rubeis
et al., 2014). Here we present the latest iteration of this approach
that incorporates structural variation. We use the TADAmodel to
integrate data from small de novo deletions in 4,687 ASD cases
and 2,100matched sibling controls from the SSC and AGP (Pinto
et al., 2014) alongside exome data of 5,563 ASD cases and
13,321 controls in the combination of the SSC (Iossifov et al.,
2014) and ASC (De Rubeis et al., 2014) datasets. This compre-
hensive analysis identifies 65 ASD genes (FDR% 0.1), including
28 at the more stringent threshold of FDR% 0.01 (Table 4). The
TADA framework provides a common standard of association
that enables researchers to choose an association threshold
tailored to their needs (Table S6).
These 65 ASD risk genes show enrichment for protein-protein
interactions (PPIs) and coalesce into a PPI network with two
distinct sub-networks corresponding to genes involved in chro-
matin regulation and the synapse (Figure 7), consistent with pre-
vious analyses (Chang et al., 2015; Li et al., 2014; Parikshak
et al., 2013; Pinto et al., 2014). One explanation for how these
two sets of genes both contribute to the ASD phenotype is that
the genes involved in chromatin regulation may regulate the
expression of the synaptic genes, a hypothesis supported by
recent analyses of the regulatory targets of CHD8, an ASD
gene and chromatin regulator, though these data do not estab-
lish clear directionality in this relationship (Cotney et al., 2015;
Sugathan et al., 2014).
Our data also lend support to the female protective effect
(FPE) hypothesis as a mechanism for the increased male preva-
lence in ASD through the observation of an increased burden of
de novo mutations in female probands than male probands (Fig-
ures 2E and 2F). Further support of the FPE hypothesis comesform a DAPPLE PPI network (Rossin et al., 2011). The seed genes are shown as
ns were identified; the distribution of male and female mutations in the network
as gray lines (edges) and additional genes are pulled into the network to form
by the large ovals). All seed and network genes in each oval were submitted to
jamini Hochberg corrected p values.
Table 4).
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from the observation that mutations in male and female pro-
bands target a common set of genes (Figure 7), as opposed to
an independent set of genes contributing male-specific risk.
The importance of large dnCNVs in human disorders,
including disorders of childhood neurodevelopment, has been
appreciated for over 30 years (Dobyns et al., 1983; Ewart et al.,
1993; Ledbetter et al., 1981; Schmickel, 1986). Considerable
effort has gone into identifying critical regions and critical genes
that are responsible for the associated neurodevelopmental
phenotypes. While there have been some notable successes in
this endeavor, for example UBE3A in Angelman Syndrome (Mat-
suura et al., 1997), the majority of risk loci have been difficult to
reduce to a single critical gene. By considering the intersection
of de novo mutations in the genes targeted by dnCNVs, we
were able to address the question of whether ASD risk is medi-
ated by a single high-effect risk gene in either small or large
dnCNVs.
Three strands of evidence support a role for such a critical
gene in small de novo deletions. First, the ratio of mutations be-
tween probands and siblings is similar between dnLoF, which
affect single genes, and small de novo deletions (Figure 4). Sec-
ond, small de novo deletions in probands with ASD are greatly
enriched for genes associated with ASD from exome analysis
(Figures 5 and 6). Finally, we observe no instances of multiple
genes associated with ASD (FDR% 0.1) mapping within a single
small de novo deletion.
In contrast, two strands of evidence support the hypothesis
that multiple risk genes are present within large dnCNVs: First,
NVIQ is inversely related to the number of genes within dnCNVs
in probands (Figure S6). Second, many large CNVs contain suf-
ficient numbers of genes that numerous ASD risk genes would
be expected based solely on the fact that 800 genes are likely
contributing to ASD risk (He et al., 2013; Sanders et al., 2012).
Our data also support the hypothesis that genes within
large dnCNVs carry modest individual effects. Notably, we find
no evidence that significant risk genes identified via exome
sequencing overlap with those mapping within large dnCNVs
(Figure 6B). This finding is not altered by restricting the
search to dnLoF mutations within large de novo deletions or
dnMissense mutations in large de novo duplications (Figure 5C).
Of course, there is considerable evidence that, cumulatively,
large CNVs mediate large effects as has been noted throughout
the literature (Itsara et al., 2010; Pinto et al., 2010, 2014; Sanders
et al., 2011) and further supported by our observation here that
large CNVs are rarely inherited, regardless of genomic location
(Figures 2 and 4).
Given our approach, the current analysis does not preclude
the presence of large effect non-coding mutations within these
intervals. Moreover, if a single large-effect gene was present
within a dnCNV in which a mutation led to a more severe pheno-
type, such as a structural brain abnormality or lethality, this
would explain the observation of a paucity of dnLoF mutations
mapping within CNVs in this ASD cohort (Figure 6B).
While we have used a threshold of seven genes to distinguish
between small and large dnCNVs, our results are robust to vary-
ing the threshold between three and ten genes. A more general
statement of this model is that dnCNV size is: (1) positively corre-
lated to the number of ASD risk genes contained within; and (2)1230 Neuron 87, 1215–1233, September 23, 2015 ª2015 Elsevier Incnegatively correlated to the ASD risk mediated per gene. Of
note, this model achieves a balance in the phenotypic contribu-
tion of de novo mutations across the spectrum of mutation
sizes, so that a dnLoF in a single gene and large multigenic
dnCNV can have a similar contribution to the ASD phenotype
(Figure 3A).
Overall, through an integrative analysis of de novomutations in
ASD, we further clarify the genomic architecture of ASD, esti-
mating that 50% of dnCNVs/dnLoFs mediate ASD risk, that
more than 200 CNV risk loci and 800 risk genes are vulnerable
to de novo mutation, and that de novo mutations contribute to
the ASD phenotype in at least 11% of simplex ASD cases. We
also provide further clarification of the relationship between de
novo ASD risk mutations and intellectual disability. While we
replicate the reported correlation of lower IQ with the presence
of a de novo mutation, we find de novo mutations across the
entire IQ distribution, with an excess burden of mutations in
the highest confidence ASD risk genes, even in males with IQ
above 130. In short, the data support the conclusion that
large-effect de novo mutations contribute to ASD risk apart
from intellectual disability.
Using a rigorous approach to assessing the significance of
recurrent de novo mutations, we identify 71 independent ASD
risk loci (FDR% 0.1), composed of eight ASD risk loci (Table 2)
and 65 ASD risk genes (Table 4) with NRXN1 and SHANK3
appearing in both lists. Finally, using a systems biological
approach, we show that these 65 genes form a single network
of protein-protein interactions that is enriched for genes involved
in chromatin regulation and the synapse (Figure 7).
EXPERIMENTAL PROCEDURES
This study was overseen by the IRB at both Yale (HIC 0301024156) and UCSF
(IRB: 14-14726 Ref: 146621). The data reported in this paper can be down-
loaded from SFARI Base (http://sfari.org/resources/sfari-base).
Genotyping
Illumina SNP genotyping data were generated for 10,220 individuals from
2,591 families from the SSC. Three types of genotyping array were used,
with all family members run on the same array type: 333 families on the
1Mv1, 1,189 families on the 1Mv3, and 1,069 on the Omni2.5. A complete
list of individuals is shown in Table S1.
Quality Control
All individuals included in the analysis passed stringent quality control mea-
sures, including genotypic identity within the family using PLINK (Purcell
et al., 2007); sex check based on chromosome X heterozygosity and sex chro-
mosome LRR (Figure S1); genotypes matching the exome data; genotyping
rateR 97%; and all members of the family passing the quality metrics of the
CNV detection algorithms.
CNV Detection
Three algorithms were used to predict CNVs with default settings: PennCNV
(Wang et al., 2007), QuantiSNPv2.3 (Colella et al., 2007), and GNOSIS
(Sanders et al., 2011). The CNVs from the three algorithms were merged using
CNVision (https://sourceforge.net/projects/cnvision/). Based on assessment
of dnCNVs in technical replicates, a pCNV threshold of %1 3 109 was
used for de novo prediction (Figure S2) and%1 3 104 for rare inherited pre-
diction (Figure S3). Only CNVs with a population frequency%0.1% based on
parental data and the Database of Genomic Variation (MacDonald et al., 2014)
were included in the analysis. A complete list of de novo (Table S2) and rare
inherited (Table S3) CNVs are included in the SOM..
Assessment of De Novo Recurrence
The significance of observing multiple dnCNVs at the same genomic loci was
assessed using the method described previously (Sanders et al., 2011). The
degree of overlap between dnCNVs in siblings was used to estimate the
number of potential genomic locations a dnCNV occurred at, under the null
distribution based on the unseen species model. Using this estimate, we
predicted the likelihood of observing two or more dnCNVs in probands at a
given location based on permutation testing.
Observed versus Expected TADA Values
To estimate the expected distribution of TADA values in small or large CNVs
(Figure 6), we used a permutation test. For each observed dnCNV the same
number of genes was selected at random, based on the mutation rate of those
genes within CNVs (Figure S10–S12). The corresponding TADA FDR q values
were obtained. This was repeated for all the dnCNVs in the probands. The
TADA scores were then sorted from high to low. This process was repeated
100 times and the median of the highest score from 100 iterations was used
as the expected value to compare with the highest score from the observed
TADA values. This was repeated with the second highest, third highest, etc.
to account for all the observed genes.
SUPPLEMENTAL INFORMATION
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12 figures, and 6 tables and can be found with this article online at http://dx.
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